Eli Lilly and Company Earnings Watch & Stock Update

Analysts Expect Eli Lilly to Post Revenue Growth in 3Q17

The stock decreased 0.06% or $0.05 during the last trading session, reaching $87.18. The company's P/E was valued at 37.81 as it measures its current share price to its per-share earnings. Insiders have sold 990,000 shares of company stock valued at $82,949,650 in the last 90 days. About 2.74 million shares traded.

Depending on the earnings numbers reported, Eli Lilly and Company (NYSE:LLY) stock may see increased volatility following the report. It has underperformed by 38.95% the S&P500. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. During the last month, the stock has changed 13.08% and performed -31.31% over the last 6 months. The biggest holder now is Dr. John C Lechleiter PhD who owns 834,291 shares (0.08% of those outstanding), whilst Sidney Taurel holds 341,806 (0.03% of shares outstanding) and Dr. Jan M. Lundberg, PhD holds 147,002 (0.01% of shares outstanding). Rmb Capital Management Limited Company owns 36,198 shares or 0.07% of their USA portfolio. Daiwa Secs Gp Inc accumulated 3,600 shares. Praxair, Inc. (NYSE:PX) has risen 17.42% since October 23, 2016 and is uptrending. It has outperformed by 18.90% the S&P500. (NYSE:PX) to report earnings on October, 26. During the same quarter a year ago, the company posted $0.88 EPS.

Sell-side analysts on Wall Street are anticipating that Eli Lilly and Company (NYSE:LLY) will report earnings of $1.03 per share when the company issues their quarterly report today. CEMI's SI was 116,600 shares in October as released by FINRA. More interesting news about Praxair, Inc.

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products.

LLY has been the topic of a number of analyst reports. TheStreet upgraded Eli Lilly and from a "c+" rating to a "b+" rating in a research report on Tuesday, July 25th. Penserra Capital Management LLC now owns 2,024 shares of the company's stock worth $170,000 after acquiring an additional 176 shares during the last quarter. The firm has "Neutral" rating given on Friday, November 25 by Atlantic Securities. That puts the market capitalization at $95.03 bln. The stock has "Underperform" rating by Bank of America on Friday, January 22. (NYSE:PX) rating on Tuesday, October 17. Its down 0.14, from 1.04 in 2017Q1. The number of shares now owned by investors are 71.94 mln. 94 funds opened positions while 226 raised stakes. 823.00 million shares or 0.09% more from 822.25 million shares in 2017Q1 were reported. These holdings make up 75.93% of the company's outstanding shares. Retirement Sys Of Alabama reported 138,601 shares stake. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. Westfield LP holds 0.93% of its portfolio in Eli Lilly and Co (NYSE:LLY) for 1.33M shares. Cincinnati Finance owns 113,000 shares for 0.71% of their portfolio. The option since executed brings Luciano ownership to 3143 shares. Steadfast Cap Mngmt Limited Partnership invested 1.06% in Praxair, Inc. Its down 2.1% from 119,100 shares previously. Counselors stated it has 0.07% of its portfolio in Praxair, Inc. Bp Public Ltd Company owns 35,000 shares or 0.17% of their USA portfolio. Natixis has 0.4% invested in Eli Lilly and Co (NYSE:LLY) for 430,709 shares. Cowen & Co maintained the shares of LLY in report on Saturday, August 22 with "Outperform" rating.

Q3 results: Revenues: $5,658M (+9.0%); Operating Income: $605.5M (-35.8%); Net Income: $555.6M (-28.6%); EPS: $0.53 (-27.4%); Non-GAAP EPS: $1.05 (+19.3%).

Since May 4, 2017, it had 0 insider buys, and 3 insider sales for $4.05 million activity.

State Of Wisconsin Investment Board decreased Waters Corp (NYSE:WAT) stake by 53,930 shares to 49,155 valued at $9.04 million in 2017Q2. Shares for $153,482 were sold by Barnes Melissa S on Monday, June 12.

Eli Lilly and Company (LLY) shares ended at $87.18 with 4.9 mln shares exchanging hands. Therefore 60% are positive.

Eli Lilly has raised its 2017 adjusted EPS outlook to US$4.15 to US$4.25 from US$4.10 from US$4.20. The company was maintained on Tuesday, August 2 by Argus Research. $2.07 million worth of Eli Lilly and Co (NYSE:LLY) was sold by Conterno Enrique A on Thursday, May 4. The count of Hold ratings in that period was 16. Jefferies maintained it with "Buy" rating and $9200 target in Tuesday, May 30 report. The firm has "Overweight" rating by Morgan Stanley given on Friday, December 16. Ipswich has 0.32% invested in Eli Lilly and Co (NYSE:LLY) for 8,280 shares.

Several other institutional investors and hedge funds have also recently modified their holdings of the business.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Related:

Comments


Other news